1. Transanal minimally invasive surgery for benign and malignant rectal neoplasia
- Author
-
Mark A. Talamini, Elisabeth C. McLemore, Santiago Horgan, Lynn A. Weston, Sonia Ramamoorthy, Garth R. Jacobsen, and Alisa M. Coker
- Subjects
Adenoma ,Adult ,Male ,medicine.medical_specialty ,Endoscope ,Colorectal cancer ,medicine.medical_treatment ,Urinary system ,Anal Canal ,Carcinoid Tumor ,Adenocarcinoma ,Lesion ,Postoperative Complications ,medicine ,Humans ,Minimally Invasive Surgical Procedures ,Aged ,Retrospective Studies ,Aged, 80 and over ,Rectal Neoplasms ,business.industry ,Rectum ,Atrial fibrillation ,General Medicine ,Middle Aged ,Microsurgery ,medicine.disease ,Institutional review board ,Surgery ,Treatment Outcome ,Female ,medicine.symptom ,business - Abstract
Background Transanal minimally invasive surgery (TAMIS), an alternative technique to transanal endoscopic microsurgery, was developed in 2009. Herein, we describe our initial experience using TAMIS for benign and malignant rectal neoplasia. Methods This is an institutional review board approved, retrospective case series report. Results TAMIS was performed in 32 patients for rectal adenoma (13), adenocarcinoma (16), and carcinoid (3). There were 14 women, with mean age 62 ± 15 years and body mass index 28 ± 5 kg/m2. Lesion size ranged from .5 to 8.5 cm, distance from the dentate line 1 to 11 cm, and circumference of the lesion 10% to 100%. The mean operative time was 123 ± 62 minutes. Mean hospital length of stay was 2.5 ± 2 days. Complications included urinary tract infection (1), Clostridium difficile diarrhea (1), atrial fibrillation (1), rectal stenosis (1), and rectal bleeding (1). Conclusion TAMIS using a disposable transanal access platform is a safe and effective method to remove rectal lesions in this case series.
- Published
- 2014